TABLE 1

Clinical characteristics of postnatal transmitting and matched nontransmitting HIV-1-infected mothers from the PROMISE 1077BF study

TABLE 1
  • a Min, minimum; max, maximum; M, male; F, female.

  • b In the maternal triple-ART arm, the mother received lopinavir-ritonavir (LPV-RTV) plus tenofovir-emtricitabine (TDF/FTC). In the infant prophylaxis arm, the infant received nevirapine (NVP). In the AP observation follow-up, the mother received a triple-ART regimen until the week 1 postpartum visit.